8-K: Inspire Medical Systems Reports Strong Q1 2025 Results, Updates Full-Year Outlook

Inspire Medical Systems announces a 23% year-over-year revenue increase and earnings per share of $0.10 for the first quarter of 2025, while maintaining its full-year revenue guidance and raising its EPS guidance.

Summary

• Inspire Medical Systems reported a revenue of $201.3 million for Q1 2025, a 23% increase compared to $164.0 million in Q1 2024.
• U.S. revenue increased by 24% to $193.6 million, while revenue outside the U.S. decreased by 6% to $7.7 million.
• The company achieved a gross margin of 84.7% in Q1 2025, slightly lower than the 84.9% in Q1 2024.
• Operating expenses increased by 11% to $172.1 million, driven by investments in sales and corporate costs, partially offset by reduced R&D and patient marketing expenses.
• The operating loss improved by 90% to $1.5 million, reflecting revenue growth and operating leverage.
• Net income was $3.0 million, a significant improvement from the net loss of $10.0 million in the prior year period.
• Adjusted EBITDA was $33.2 million, compared to $11.9 million in the corresponding prior year period.
• Diluted net income per share was $0.10, compared to a net loss of $0.34 per share in the prior year period.
• As of March 31, 2025, cash, cash equivalents, and investments totaled $414.0 million, down from $516.5 million on December 31, 2024.
• Inspire is maintaining its full year 2025 revenue guidance of between $940 million to $955 million, which represents growth of 17% to 19% over full year 2024 revenue of $802.8 million.
• The company is maintaining its full year 2025 gross margin guidance of 84% to 86%.
• Inspire is increasing diluted net income per share guidance for the full year 2025 to between $2.20 to $2.30, compared to the prior guidance of $2.10 to $2.20 per share.
• The company surpassed 100,000 patients receiving Inspire therapy and is initiating the full launch of the Inspire V system in the U.S. this month.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, increased guidance, and significant milestones achieved. The tone is optimistic and confident, reflecting the company's growth and market position.

Positives

• Strong revenue growth of 23% year-over-year in Q1 2025.
• Significant improvement in earnings per share, moving from a loss of $0.34 to a profit of $0.10.
• Gross margin remains high at 84.7%.
• Operating loss significantly reduced by 90%.
• Adjusted EBITDA increased substantially from $11.9 million to $33.2 million.
• Full year EPS guidance increased from $2.10-$2.20 to $2.20-$2.30.
• The company surpassed 100,000 patients receiving Inspire therapy.
• The full launch of the Inspire V system is commencing in the U.S.

Negatives

• Revenue outside the U.S. decreased by 6% in Q1 2025.
• Operating expenses increased by 11% due to investments in sales and corporate costs.
• Cash, cash equivalents, and investments decreased from $516.5 million to $414.0 million.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include commercial success and market acceptance of Inspire therapy, competition, regulatory proceedings, and dependence on third-party suppliers.
• Challenges experienced by patients in obtaining prior authorization could impact the company's performance.
• The impact of glucagon-like peptide 1 class of drugs on demand for Inspire therapy is a potential risk factor.
• The company's ability to accurately forecast customer demand for Inspire therapy and manage its inventory is a risk.

Future Outlook

Inspire is maintaining its full year 2025 revenue guidance of between $940 million to $955 million, which represents growth of 17% to 19% over full year 2024 revenue of $802.8 million. The company is maintaining its full year 2025 gross margin guidance of 84% to 86%. Inspire is increasing diluted net income per share guidance for the full year 2025 to between $2.20 to $2.30.

Management Comments

• We are very proud of our performance in the first quarter which included strong revenue growth and continued progress on profitability.
• We achieved a tremendous milestone with over 100,000 patients receiving Inspire therapy and we are still just getting started in growing awareness and adoption, said Tim Herbert, Chairman and CEO of Inspire Medical Systems.
• We are now ready to launch of the Inspire V system and look forward to initiating the full launch this month in the U.S.

Industry Context

Inspire Medical Systems operates in the medical technology industry, specifically focusing on solutions for obstructive sleep apnea. The company competes with traditional treatments like CPAP and surgical alternatives. The announcement highlights the company's growth and market penetration in a competitive landscape, with a focus on innovative neurostimulation technology.

Comparison to Industry Standards

• Inspire's revenue growth of 23% in Q1 2025 is strong compared to other medical device companies.
• The gross margin of 84.7% is also competitive within the medical technology sector.
• Companies like ResMed, which also focus on sleep apnea solutions, are key competitors.
• The milestone of 100,000 patients receiving Inspire therapy demonstrates significant market adoption compared to other novel therapies.
• The company's focus on innovation, such as the Inspire V system, positions it well against competitors offering more traditional treatments.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and increased guidance.
• Employees may experience increased job security and growth opportunities due to the company's expansion.
• Customers (patients) will benefit from the launch of the Inspire V system and continued innovation.
• Suppliers and partners may see increased business opportunities due to the company's growth.

Next Steps

• Full launch of the Inspire V system in the U.S. in May 2025.
• Continued commercial expansion and physician training.
• Further penetration of existing markets and expansion into new geographical locations.
• Ongoing research and development to drive breakthrough technology innovation and expanded indications.

Key Dates

Keywords

Inspire Medical Systems, obstructive sleep apnea, neurostimulation, revenue, earnings per share, Inspire therapy, Adjusted EBITDA, gross margin, Inspire V, financial results